Literature DB >> 21933854

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.

Anna Skowronska1, Belinda Austen, Judith E Powell, Victoria Weston, David G Oscier, Martin J S Dyer, Estella Matutes, Guy Pratt, Christopher Fegan, Paul Moss, Malcolm A Taylor, Tatjana Stankovic.   

Abstract

Ataxia telangiectasia patients, with constitutional bi-allelic ATM mutations, have a marked risk of lymphoid tumors and ATM mutation carriers have a smaller risk of cancer. Sporadic ATM mutations occur in 10-20% of chronic lymphocytic leukemia and are often associated with chromosome 11q deletions which cause loss of an ATM allele. The role of constitutional ATM mutations in the pathogenesis of chronic lymphocytic leukemia is unknown. Here we investigated the frequency of constitutional ATM mutations in either of two chronic lymphocytic leukemia cohorts, those with and without a chromosome 11q deletion. We found that in comparison to controls, constitutional pathogenic ATM mutations were increased in patients with chromosome 11q deletions (6 of 140 vs. 0 of 281, P = 0.001) but not in those without 11q deletions (2 of 178 vs. 0 of 281, P = 0.15). These results suggest that ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but rather influences rapid disease progression through ATM loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933854      PMCID: PMC3248944          DOI: 10.3324/haematol.2011.048827

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.

Authors:  Antonio Cuneo; Renato Bigoni; Gian Matteo Rigolin; Maria Grazia Roberti; Antonella Bardi; Francesco Cavazzini; Raffaella Milani; Claudia Minotto; Alessia Tieghi; Matteo Della Porta; Paola Agostini; Elisa Tammiso; Massimo Negrini; Gianluigi Castoldi
Journal:  Haematologica       Date:  2002-01       Impact factor: 9.941

2.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

3.  ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer.

Authors:  T Stankovic; A M Kidd; A Sutcliffe; G M McGuire; P Robinson; P Weber; T Bedenham; A R Bradwell; D F Easton; G G Lennox; N Haites; P J Byrd; A M Taylor
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

4.  Cancer risks and mortality in heterozygous ATM mutation carriers.

Authors:  Deborah Thompson; Silvia Duedal; Jennifer Kirner; Lesley McGuffog; James Last; Anne Reiman; Philip Byrd; Malcolm Taylor; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

5.  Characterization of ATM gene mutations in 66 ataxia telangiectasia families.

Authors:  N Sandoval; M Platzer; A Rosenthal; T Dörk; R Bendix; B Skawran; M Stuhrmann; R D Wegner; K Sperling; S Banin; Y Shiloh; A Baumer; U Bernthaler; H Sennefelder; M Brohm; B H Weber; D Schindler
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

Review 6.  Familial CLL: genes and environment.

Authors:  Lynn R Goldin; Susan L Slager
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

7.  Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.

Authors:  Andy C Rawstron; Fiona L Bennett; Sheila J M O'Connor; Marwan Kwok; James A L Fenton; Marieth Plummer; Ruth de Tute; Roger G Owen; Stephen J Richards; Andrew S Jack; Peter Hillmen
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

8.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

Authors:  Belinda Austen; Anna Skowronska; Claire Baker; Judith E Powell; Anne Gardiner; David Oscier; Aneela Majid; Martin Dyer; Reiner Siebert; A Malcolm Taylor; Paul A Moss; Tatjana Stankovic
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

9.  RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling.

Authors:  Grant S Stewart; Tatjana Stankovic; Philip J Byrd; Thomas Wechsler; Edward S Miller; Aarn Huissoon; Mark T Drayson; Stephen C West; Stephen J Elledge; A Malcolm R Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

10.  Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults.

Authors:  R de Tute; M Yuille; D Catovsky; R S Houlston; P Hillmen; A C Rawstron
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

View more
  15 in total

1.  ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2012-01       Impact factor: 9.941

2.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

Authors:  Lesley-Ann Sutton; Viktor Ljungström; Larry Mansouri; Emma Young; Diego Cortese; Veronika Navrkalova; Jitka Malcikova; Alice F Muggen; Martin Trbusek; Panagiotis Panagiotidis; Frederic Davi; Chrysoula Belessi; Anton W Langerak; Paolo Ghia; Sarka Pospisilova; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

3.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

Authors:  Gerard Lozanski; Amy S Ruppert; Nyla A Heerema; Arletta Lozanski; David M Lucas; Amber Gordon; John G Gribben; Vicki A Morrison; Kanti M Rai; Guido Marcucci; Richard A Larson; John C Byrd
Journal:  Leuk Lymphoma       Date:  2012-06-02

Review 4.  Molecular pathogenesis of chronic lymphocytic leukemia.

Authors:  Gianluca Gaidano; Robin Foà; Riccardo Dalla-Favera
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

5.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Intrinsic mitochondrial DNA repair defects in Ataxia Telangiectasia.

Authors:  Nilesh K Sharma; Maria Lebedeva; Terace Thomas; Olga A Kovalenko; Jeffrey D Stumpf; Gerald S Shadel; Janine H Santos
Journal:  DNA Repair (Amst)       Date:  2013-12-15

7.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Authors:  Ferran Nadeu; Julio Delgado; Cristina Royo; Tycho Baumann; Tatjana Stankovic; Magda Pinyol; Pedro Jares; Alba Navarro; David Martín-García; Sílvia Beà; Itziar Salaverria; Ceri Oldreive; Marta Aymerich; Helena Suárez-Cisneros; Maria Rozman; Neus Villamor; Dolors Colomer; Armando López-Guillermo; Marcos González; Miguel Alcoceba; Maria José Terol; Enrique Colado; Xose S Puente; Carlos López-Otín; Anna Enjuanes; Elías Campo
Journal:  Blood       Date:  2016-02-02       Impact factor: 22.113

8.  Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry; Pankaj Taneja
Journal:  Clin Med Insights Oncol       Date:  2013-06-03

9.  Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.

Authors:  M J J Rose-Zerilli; J Gibson; J Wang; W Tapper; Z Davis; H Parker; M Larrayoz; H McCarthy; R Walewska; J Forster; A Gardiner; A J Steele; C Chelala; S Ennis; A Collins; C C Oakes; D G Oscier; J C Strefford
Journal:  Leukemia       Date:  2016-02-05       Impact factor: 11.528

10.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Authors:  Brian A Walker; Eileen M Boyle; Christopher P Wardell; Alex Murison; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; David C Johnson; Martin F Kaiser; Lorenzo Melchor; Lauren I Aronson; Matthew Scales; Charlotte Pawlyn; Fabio Mirabella; John R Jones; Annamaria Brioli; Aneta Mikulasova; David A Cairns; Walter M Gregory; Ana Quartilho; Mark T Drayson; Nigel Russell; Gordon Cook; Graham H Jackson; Xavier Leleu; Faith E Davies; Gareth J Morgan
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.